The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR -Mutated Non–Small Cell Lung Cancer
Open accessPublished version of a preprint
Abstract
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an antibody–drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. This phase I, dose escalation/expansion study included patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with prior EGFR tyrosine kinase inhibitor (TKI) therapy. Among 57 patients receiving HER3-DXd 5.6 mg/kg intravenously once every 3 weeks, the confirmed objective response rate by blinded independent central review (Response Evaluation Criteria in Solid Tumors v1.1) was 39% [95% confidence interval (CI), 26.0–52.4], and median progression-free survival was 8.2 (95% CI, 4.4–8.3) months. Responses were observed in patients with known and unknown EGFR TKI resistance mechanisms. Clinical activity was observed across a broad range of HER3 membrane expression. The most common grade ≥3 treatment-emergent adverse events were hematologic toxicities. HER3-DXd has clinical activity in EGFR TKI–resistant cancers independent of resistance mechanisms, providing an approach to treat a broad range of drug-resistant cancers. Significance: In metastatic EGFR-mutated NSCLC, after disease progression on EGFR TKI therapy, treatment approaches include genotype-directed therapy targeting a known resistance mechanism or chemotherapy. HER3-DXd demonstrated clinical activity spanning known and unknown EGFR TKI resistance mechanisms. HER3-DXd could present a future treatment option agnostic to the EGFR TKI resistance mechanism. See related commentary by Lim et al., p. 16. This article is highlighted in the In This Issue feature, p. 1
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · cited 1×
“CR 1 (2) 1 (2) PR 21 (37) 16 (36) SD 19 (33) 13 (30) PD 9 (16) 8 (18) NE 7 (12) 6 (14) DCR,a % (n) [95% CI] 72 (41) 68 (30) [58.”
Self-citationOverall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationTrastuzumab deruxtecan in previously treated HER2-positive gastric cancer
Shitara, K., Bang, Y.-J., Iwasa, S., Sugimoto, N., Ryu, M.-H., Sakai, D., Chung, H.-C., Kawakami, H., Yabusaki, H., Lee, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004413 · Cited by 1,333 · cited 3×
“An ADC using the same linker-payload technology but directed against HER2 [trastuzumab deruxtecan (T-DXd)] was recently approved for the treatment of HER2+ metastatic breast and gastric cancers (29, 30).”
Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,177
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Zhang, Y.-L., Yuan, J.-Q., Wang, K.-F., Fu, X.-H., Han, X.-R., Threapleton, D., Yang, Z.-Y., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 799
Jackman, D., Pao, W., Riely, G. J., Engelman, J. A., Kris, M. G., Jänne, P. A., Lynch, T., Johnson, B. E., & Miller, V. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.7049 · Cited by 793
Wu, S.-G., & Shih, J.-Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0777-1 · Cited by 778
Ogitani, Y., Hagihara, K., Oitate, M., Naito, H., & Agatsuma, T. (2016) · Cancer Science · doi:10.1111/cas.12966 · Cited by 751 · cited 1×
“The payload is cell membrane–permeable, which enables a bystander antitumor effect resulting in elimination of both target and surrounding tumor cells (25, 28).”
BackgroundNakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Sequist, L. V., Han, J.-Y., Ahn, M.-J., Cho, B. C., Yu, H., Kim, S.-W., Yang, J. C.-H., Lee, J. S., Su, W.-C., Kowalski, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30785-5 · Cited by 421
Self-citationSchoenfeld, A. J., Chan, J. M., Kubota, D., Sato, H., Rizvi, H., Daneshbod, Y., Chang, J. C., Paik, P. K., Offin, M., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3563 · Cited by 411
Self-citationRamalingam, S. S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B. C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.063 · Cited by 366
Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000352 · Cited by 360
Wu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.7326 · Cited by 333
Self-citationThird generation EGFR TKIs: current data and future directions
Tan, C.-S., Kumarakulasinghe, N. B., Huang, Y.-Q., Ang, Y. L. E., Choo, J. R.-E., Goh, B.-C., & Soo, R. A. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0778-0 · Cited by 311
Papadimitrakopoulou, V. A., Wu, Y.-L., Han, J.-Y., Ahn, M.-J., Ramalingam, S. S., John, T., Okamoto, I., Yang, J. C.-H., Bulusu, K. C., Laus, G., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.064 · Cited by 252
Self-citationMinari, R., Bordi, P., & Tiseo, M. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.12.02 · Cited by 187
Hashimoto, Y., Koyama, K., Kamai, Y., Hirotani, K., Ogitani, Y., Zembutsu, A., Abe, M., Kaneda, Y., Maeda, N., Shiose, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1745 · Cited by 178
Ricciuti, B., Jones, G., Severgnini, M., Alessi, J. V., Recondo, G., Lawrence, M., Forshew, T., Lydon, C., Nishino, M., Cheng, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001504 · Cited by 161
EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
Karachaliou, N., Fernández-Bruno, M., Bracht, J. W. P., & Rosell, R. (2018) · Translational Cancer Research · doi:10.21037/tcr.2018.10.06 · Cited by 156
Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., Westphal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43678-6 · Cited by 124
Thirty Years of HER3: From Basic Biology to Therapeutic Interventions
Haikala, H. M., & Janne, P. A. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4465 · Cited by 121
Yonesaka, K., Takegawa, N., Watanabe, S., Haratani, K., Kawakami, H., Sakai, K., Chiba, Y., Maeda, N., Kagari, T., Hirotani, K., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0517-4 · Cited by 103
Pulmonary toxicity of systemic lung cancer therapy
Long, K., & Suresh, K. S. (2020) · Respirology · doi:10.1111/resp.13915 · Cited by 103
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer
Koganemaru, S., Kuboki, Y., Koga, Y., Kojima, T., Yamauchi, M., Maeda, N., Kagari, T., Hirotani, K., Yasunaga, M., Matsumura, Y., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0452 · Cited by 90
Rebuzzi, S. E., Alfieri, R. R., Monica, S. L., Minari, R., Petronini, P. G., & Tiseo, M. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102820 · Cited by 83
Bauml, J. M., Cho, B. C., Park, K., Lee, K. H., Cho, E. K., Kim, D., Kim, S., Haura, E. B., Sabari, J. K., Sanborn, R. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9006 · Cited by 69
Self-citationPrognostic significance of HER3 in patients with malignant solid tumors
Li, Q., Zhang, R., Yan, H., Zhao, P., Wu, L., Wang, H., Li, T., & Cao, B. (2017) · Oncotarget · doi:10.18632/oncotarget.18007 · Cited by 62
Ebert, E. B. F., McCulloch, T., Hansen, K. H., Linnet, H., Sørensen, B. S., & Meldgaard, P. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.016 · Cited by 38
Ebert, E. B. F., McCulloch, T., Hansen, K. H., Linnet, H., Sørensen, B. S., & Meldgaard, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.020 · Cited by 27
ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers
Kawano, O., Sasaki, H., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.05.030 · Cited by 25
Hui, H. B., Yang, L. L., Wang, X., & Yao, L. D. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s157370 · Cited by 21
Yang, C., Hung, J., Tsai, M., Wu, K., Liu, T., Chou, S., Lee, J., Hsu, J., Huang, M., & Chong, I. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0130-0 · Cited by 20
Ueno, S., Hirotani, K., Abraham, R., Blum, S., Frankenberger, B., Redondo-Müller, M., Bange, J., Ogitani, Y., Zembutsu, A., Morita, K., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3092 · Cited by 7
Research works printed but not linked: 4
- 2021, Rybrevant (amivantamab) [US package insert]
- Haikala, 2020, EGFR inhibition enhances the cellular uptake and antitumor activity of the novel HER3 antibody drug conjugate U3-1402, Cancer Res, 80, 10.1158/1538-7445.AM2020-5192 · doi:10.1158/1538-7445.am2020-5192
- Yonemori, 2019, Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: updated results from a phase I/II trial, Ann Oncol, 30, iii48, 10.1093/annonc/mdz100.002 · doi:10.1093/annonc/mdz100.002
- Yu, 2019, Preliminary phase 1 results of U3-1402—a Novel HER3-targeted antibody-drug conjugate-in EGFR TKI-resistant EGFR-mutant NSCLC, J Thorac Oncol, 14, S336, 10.1016/j.jtho.2019.08.677 · doi:10.1016/j.jtho.2019.08.677
Cited by
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
Cooper, A. J., Sequist, L. V., & Lin, J. J. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00639-9 · Cited by 508
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Powell, C. A., Modi, S., Iwata, H., Takahashi, S., Smit, E. F., Siena, S., Chang, D.-Y., Macpherson, E., Qin, A., Singh, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100554 · Cited by 270
Shi, X., Wang, X., Yao, W., Shi, D., Shao, X., Lu, Z., Chai, Y., Song, J., Tang, W., & Wang, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01885-2 · Cited by 258
Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01909 · Cited by 188
Metadata
- Authors
- Jänne, P. A., Baik, C., Su, W.-C., Johnson, M. L., Hayashi, H., Nishio, M., Kim, D.-W., Koczywas, M., Gold, K. A., Steuer, C. E., Murakami, H., Yang, J. C.-H., Kim, S.-W., Vigliotti, M., Shi, R., Qi, Z., Qiu, Y., Zhao, L., Sternberg, D., Yu, C., & Yu, H. A.
- Venue
- Cancer Discovery
- Published
- 2021-09-21
- Volume
- 12
- Issue
- 1
- Pages
- 74-89
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3200329827
- Cited by
- 289
- References
- 36
- FWCI
- 29.64
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-06-02)
- Open access
- hybrid
- Funders
- Daiichi Sankyo, Inc. American Cancer Society (CRP-17-111-01-CDD)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.